Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now

Corporate Profile

Investor Presentation

Read Now

highlightbg1

Our Pipeline

Learn More
highlightbg2
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

March 5, 2021

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer

March 2, 2021

Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

February 26, 2021

BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan

Key Metrics

Key Metrics

  • 5,200+

    Employees

  • 1,600+

    Clinical team

  • 5

    Continents

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept